Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Aim of the study is investigate of expression levels of serum specific miRNA221 and miRNA222 as a biomarker in NSCLC.Thirty-two NSCLC cases and 30 healthy control cases that were diagnosed at Yedikule Chest Diseases and Chest Surgery, Training and Research Hospital were included in this study. In the study were used RT-PCR based miRNA (miR-qRT-PCR) detection methods. In NSCLC patients in accordance with control, miR221 and miR222 are expressed 1.46 and 1.63-fold, respectively, and while the difference of expression is statistically significant for miR221 (p:0.0001), significant difference did not be detected for miR222 (p:0.08)

Table 1. The fold change of miR221 and miR222

Gene	Average DCt	Average DCt	2^-DCt	2^-DCt	%95 C.I	Fold change	p-value
	NSCLC	Control	NSCLC	Control
miR221	4.63	5.18	0.040444	0.027666	(1.39 - 1.53)	1.46	0.000095
miR222	3.16	3.87	0.111545	0.068384	(1.05 - 2.21)	1.63	0.084470
	Average DCt	Average DCt	2^-DCt	2^-DCt	%95 C.I	Fold change	p-value
	T3+T4	T1+T2	T3+T4	T1+T2
miR221	4.01	5.40	0.062144	0.023678	(2.23- 3.01)	2.62	0.000165
miR222	2.23	4.31	0.213465	0.050513	(2.12- 6.34)	4.23	0.007449
	Average DCt	Average DCt	2^-DCt	2^-DCt	%95 C.I	Fold change	p-value
	Metastases (+)	Metastases (-)	Metastases (+)	Metastases (-)
miR221	3.62	4.84	0.081488	0.034958	(1.66- 3.00)	2.33	0.014585
miR222	5.36	2.49	0.024360	0.177885	(0.06- 0.22)	0.14	0.006675
	Average DCt	Average DCt	2^-DCt	2^-DCt	%95 C.I	Fold change	p-value
	Advanced stage	Early stage	Advanced stage	Early stage
miR221	7.06	7.59	0.007485	0.005190	(1.36- 1.52)	1.44	0.000387
miR222	1.95	2.56	0.258048	0.169796	(1.43- 1.61)	1.52	0.000302

Keywords:NSCLC, biomarker, gene expression, miR221, miR222.

Rating:

Share or cite this content

Citations should be made in the following way:
Y. Musteri Oltulu, E. Coskunpinar, E. Aynaci, P. Yildiz, I. Yaylim (Istanbul, Turkey). The value of miR221 and miR222 as a biomarker in non small cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 510

Member's Comments

No comment yet.

Related content which might interest you: Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Investigation of survivin gene expression in non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Lung cancer in women: Is it different? Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 PIWI proteins as prognostic markers in non small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015